Multigene assays and isolated tumor cells for early breast cancer treatment: time for bionetworks

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J. Clin. DOI: doi: 10.3322/caac.20073 (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet365, 1687–1717 (2005).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann. Oncol.20(8), 1319–1329 (2009).
   PubMed Web of Science ®Google Scholar
• Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N. Engl. J. Med.361(13), 1230–1233 (2009).
   PubMed Web of Science ®Google Scholar
• Green FL, Page DL, Fleming ID et al.AJCC Cancer Staging Manual (6th Edition). American Joint Commission on Cancer, IL, USA (2002).
   Google Scholar
• de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N. Engl. J. Med.361(7), 653–663 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Isolated tumor cells in breast cancer. N. Engl. J. Med.361, 1994–1995 (2009).
   PubMedGoogle Scholar
• Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann. Surg. Oncol.14(12), 3378–3384 (2007).
   PubMedGoogle Scholar
• Cote RJ, Peterson HF, Chaiwun B et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. Lancet354, 896–900 (1999).
   PubMed Web of Science ®Google Scholar
• de Mascarel I, Bonichon F, Coindre JM, Trojani M. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: revaluation with longer follow-up. Br. J. Cancer66, 523–527 (1992).
   PubMed Web of Science ®Google Scholar
• Tan LK, Giri D, Hummer AJ et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J. Clin. Oncol.26, 1803–1809 (2008).
   PubMedGoogle Scholar
• Colleoni M, Rotmensz N, Peruzzotti G et al. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement. J. Clin. Oncol.23, 1379–1389 (2005).
   PubMed Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature406, 747–752 (2000).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA98, 10869–10874 (2001).
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA100, 8418–8412 (2003).
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med.351, 2817–2826 (2004).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van’t Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347, 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N. Engl. J. Med.360(8), 790–800 (2009).
   PubMed Web of Science ®Google Scholar
• O’Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N. Engl. J. Med.355(6), 615–617 (2006).
   PubMedGoogle Scholar
• Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J. Clin. Oncol.27(8), 1337–1338 (2009).
   PubMedGoogle Scholar
• Huang CC, Bredel M. Use of gene signatures to improve risk estimation in cancer. JAMA299(13), 1605–1606 (2008).
   PubMedGoogle Scholar
• Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med.355, 560–569 (2006).
   PubMed Web of Science ®Google Scholar
• Lee TS, Kilbreath SL, Refshauge KM, Herbert RD, Beith JM. Prognosis of the upper limb following surgery and radiation for breast cancer. Breast Cancer Res. Treat.110(1), 19–37 (2008).
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Guidelines for Treatment of Cancer by Site. National Comprehensive Cancer Network, PA, USA (2009).
   Google Scholar
• Gonzalez-Angulo AM, Litton JK, Broglio KR et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J. Clin. Oncol.27(34), 5700–5706 (2009).
   PubMed Web of Science ®Google Scholar
• Curigliano G, Viale G, Bagnardi V et al. Clinical relevance of HER2 overexpression/ amplification in patients with small tumor size and node-negative breast cancer. J. Clin. Oncol.27(34), 5693–5699 (2009).
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P-L, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med.354(8), 809–820 (2006).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med.353(16), 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med.353(16), 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2/neu positive early breast cancer patients. Presented at: 29th Annual San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14–17 December 2006.
   Google Scholar
• Viani G, Afonso S, Stefano E et al. Adjuvant trastuzumab in the treatment of HER-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer7, 153 (2007).
   PubMed Web of Science ®Google Scholar
• Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev. Anticancer Ther.10(2), 123–128 (2010).
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Souter I, D’Alessandro HA, Sgroi DC. Case records of the Massachusetts General Hospital. Case 25–2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N. Engl. J. Med.361(7), 699–707 (2009).
   PubMedGoogle Scholar
• Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature458(7239), 719–724 (2009).
   PubMed Web of Science ®Google Scholar
• Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer2(5), 331–341 (2002).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell100(1), 57–70 (2000).
   PubMed Web of Science ®Google Scholar
• Friedman A, Perrimon N. Genetic screening for signal transduction in the era of network biology. Cell128, 225–231 (2007).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Personalized cancer diagnostics and therapeutics. Expert Rev. Mol. Diagn.9(3), 227–229 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Mea Culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev. Mol. Diagn.9(3), 217–221 (2009).
   PubMed Web of Science ®Google Scholar
• Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer46, 1307–1318 (1980).
   PubMedGoogle Scholar
• Schinzel AC, Hahn WC. Oncogenic transformation and experimental models of human cancer. Front. Biosci.13, 71–84 (2008).
   PubMedGoogle Scholar
• Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science318(5853), 1108–1113 (2007).
   PubMed Web of Science ®Google Scholar
• Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science321(5897), 1801–1806 (2008).
   PubMed Web of Science ®Google Scholar
• Shendure J, Ji H. Next-generation DNA sequencing. Nat. Biotechnol.26, 1135–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev. Mol. Diagn.10(3), 247–250 (2010).
   PubMed Web of Science ®Google Scholar
• Snyder M, Weissman S, Gerstein M. Personal phenotypes to go with personal genomes. Mol. Syst. Biol.5, 273 (2009).
   PubMedGoogle Scholar
• Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature461(7265), 809–813 (2009).
   PubMed Web of Science ®Google Scholar
• Stephens PJ, McBride DJ, Lin ML et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature462(7276), 1005–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Beroukhim R, Mermel CH, Porter D et al. The landscape of somatic copy-number alteration across human cancers. Nature463(7283), 899–905 (2010).
   PubMed Web of Science ®Google Scholar
• Bastiaens P. Systems biology: when it is time to die. Nature459(7245), 334–335 (2009).
   PubMed Web of Science ®Google Scholar
• Rockman MV. Reverse engineering the genotype–phenotype map with natural genetic variation. Nature456, 738–744 (2008).
   PubMed Web of Science ®Google Scholar
• Bohman T. Mathematics. Emergence of connectivity in networks. Science323(5920), 1438–1439 (2009).
   PubMedGoogle Scholar
• Roukos DH. Novel clinico–genome network modeling for revolutionizing genotype–phenotype-based personalized cancer care. Expert Rev. Mol. Diagn.10(1), 33–48 (2010).
   PubMed Web of Science ®Google Scholar
• Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature461(7261), 218–223 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics11(3), 283–287 (2010).
   PubMed Web of Science ®Google Scholar
• Ledford H. Big science: the cancer genome challenge. Nature464(7291), 972–974 (2010).
   PubMed Web of Science ®Google Scholar
• The human genome at ten. Nature464(7289), 649–650 (2010).
   PubMed Web of Science ®Google Scholar
• Ding L, Ellis MJ, Li S et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature464(7291), 999–1005 (2010).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Radiation therapy for breast cancer. N. Engl. J. Med.360(13), 1362 (2009).
   PubMedGoogle Scholar
• Roukos DH. Beyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast cancer. J. Clin. Oncol.28(17), e279–e280 (2010).
   PubMedGoogle Scholar
• Roukos DH. Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann. Surg. Oncol.16(3), 772–773 (2009).
   PubMedGoogle Scholar
• Roukos DH, Ziogas D. Human genetic and structural genomic variation: would genome-wide association studies be the solution for cancer complexity like Alexander the Great for the ‘Gordian Knot’? Ann. Surg. Oncol.16(3), 774–775 (2009).
   PubMedGoogle Scholar
• Ziogas D, Roukos DH. Genetics and personal genomics for personalized breast cancer surgery: progress and challenges in research and clinical practice. Ann. Surg. Oncol.16(7), 1771–1782 (2009).
   PubMedGoogle Scholar
• Roukos DH. Genome-wide association studies: how predictable is a person’s cancer risk? Expert Rev. Anticancer Ther.9(4), 389–392 (2009).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann. Surg. Oncol.16(4), 795–798 (2009).
   PubMedGoogle Scholar
• Collins F. Has the revolution arrived? Nature464(7289), 674–675 (2010).
   PubMed Web of Science ®Google Scholar
• Venter JC. Multiple personal genomes await. Nature464(7289), 676–677 (2010).
   PubMed Web of Science ®Google Scholar
• Roukos DH. Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics11(8), 1039–1043 (2010).
   PubMedGoogle Scholar
• Roukos DH. Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomarkers Med.4(4), DOI 110.2217/BMM.10.70 (2010) (In press).
   PubMedGoogle Scholar
• Katsios C, Roukos DH. Individual genomes and personalized medicine: life diversity and complexity. Per. Med.7(4), 347–350 (2010).
   PubMedGoogle Scholar
• Roukos DH, Katsios C, Liakakos T. Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev. Mol. Diagn.10(5), 541–545 (2010).
   PubMed Web of Science ®Google Scholar